Palo Alto Investors LLC held its position in shares of Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 295,240 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Celgene makes up about 1.8% of Palo Alto Investors LLC’s portfolio, making the stock its 15th biggest holding. Palo Alto Investors LLC’s holdings in Celgene were worth $38,343,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares during the last quarter. State Street Corp boosted its position in shares of Celgene by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares during the last quarter. Jennison Associates LLC boosted its position in shares of Celgene by 1.2% during the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after buying an additional 156,864 shares during the last quarter. Finally, FMR LLC boosted its position in shares of Celgene by 5.9% during the second quarter. FMR LLC now owns 12,594,467 shares of the biopharmaceutical company’s stock valued at $1,635,643,000 after buying an additional 697,250 shares during the last quarter. 80.17% of the stock is currently owned by institutional investors.

A number of research analysts have weighed in on CELG shares. Morgan Stanley downgraded Celgene from an “equal weight” rating to an “underweight” rating and set a $120.00 target price on the stock. in a report on Thursday, October 5th. BTIG Research reissued a “hold” rating on shares of Celgene in a report on Sunday, October 22nd. Cantor Fitzgerald reissued a “hold” rating and issued a $112.00 target price on shares of Celgene in a report on Monday, October 30th. Vetr raised Celgene from a “buy” rating to a “strong-buy” rating and set a $144.39 target price on the stock in a report on Monday, October 23rd. Finally, Oppenheimer set a $166.00 target price on Celgene and gave the company a “buy” rating in a report on Thursday, November 16th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have issued a buy rating and two have given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $139.57.

In related news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the sale, the insider now owns 3,925 shares of the company’s stock, valued at approximately $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the sale, the director now directly owns 85,551 shares in the company, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. 0.95% of the stock is owned by company insiders.

Celgene Corporation (NASDAQ:CELG) opened at $102.73 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 12 month low of $94.55 and a 12 month high of $147.17. The company has a market capitalization of $80,880.00, a PE ratio of 16.02, a PEG ratio of 0.79 and a beta of 1.77.

Celgene (NASDAQ:CELG) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the consensus estimate of $1.87 by $0.04. Celgene had a return on equity of 63.80% and a net margin of 27.36%. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the company earned $1.58 earnings per share. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. research analysts expect that Celgene Corporation will post 6.67 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://theolympiareport.com/2017/12/08/palo-alto-investors-llc-has-38343000-holdings-in-celgene-corporation-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.